MEGAN SAWYER: Open Payments
NPI 1942603790 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,435 in 62 payments from 27 companies in 2025. Trend: 2023 $865 · 2024 $1,145 · 2025 $1,435
Food & beverage: $1,435
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 7 | $212 |
| Novartis Pharmaceuticals Corporation | 12 | $195 |
| GlaxoSmithKline, LLC. | 3 | $79 |
| AstraZeneca Pharmaceuticals LP | 4 | $77 |
| Astellas Pharma US Inc | 3 | $76 |
| SHORLA ONCOLOGY INC. | 1 | $71 |
| Incyte Corporation | 3 | $69 |
| PFIZER INC. | 4 | $61 |
| Eisai Inc. | 2 | $61 |
| Genentech USA, Inc. | 2 | $50 |
Products named: KEYTRUDA, Fabhalta, OJJAARA, IMKELDI, SCEMBLIX, Lenvima, Polivy, SARCLISA.
Industry payments across MI — which companies pay providers there.
